Uric Acid Level 9.2 mg/dL: Hyperuricemia Risks and Management

Serum uric acid >6.8 mg/dL (saturation point) defines hyperuricemia. At 9.2 mg/dL, risk of clinical sequelae is significant.

Direct Consequences

• Gout: Monosodium urate crystal deposition in joints (classically 1st MTP) → acute inflammatory arthritis. Tophi with chronicity.
• Uric acid nephrolithiasis: Radiolucent stones; obstructive uropathy.
• Chronic kidney disease: Crystal‑induced tubulointerstitial injury, vascular changes.

Associated Comorbidities

• Hypertension, metabolic syndrome, insulin resistance, type 2 diabetes
• Cardiovascular disease (independent risk factor debated)
• Non‑alcoholic fatty liver disease

Management

• Lifestyle: weight loss, low‑purine diet (limit organ meats, shellfish, alcohol—especially beer), hydration (>2 L/day).
• Urath‑lowering therapy (ULT) indicated for: gout flares ≥2/year, tophi, stones, CKD stage ≥3. Allopurinol (first‑line), febuxostat, probenecid.
• Prophylaxis with colchicine/NSAID during ULT initiation.
• Treat to target: serum urate <6 mg/dL (<5 mg/dL if tophi).